GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Price-to-Owner-Earnings

ARYx Therapeutics (ARYx Therapeutics) Price-to-Owner-Earnings : (As of May. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-05), ARYx Therapeutics's share price is $0.0005. ARYx Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for ARYx Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ARYX's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.05
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-05), ARYx Therapeutics's share price is $0.0005. ARYx Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2010 was $-0.62. Therefore, ARYx Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-05), ARYx Therapeutics's share price is $0.0005. ARYx Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.62. Therefore, ARYx Therapeutics's PE Ratio without NRI for today is At Loss.


ARYx Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for ARYx Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Price-to-Owner-Earnings Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARYx Therapeutics's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYx Therapeutics's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Price-to-Owner-Earnings falls into.



ARYx Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ARYx Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0005/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ARYx Therapeutics  (OTCPK:ARYX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ARYx Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYx Therapeutics (ARYx Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.
Executives
Newhall Charles W Iii 10 percent owner 1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri 10 percent owner
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry 10 percent owner
Patrick J Kerins 10 percent owner
Forest Baskett 10 percent owner
Growth Equity Opportunities Fund, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell 10 percent owner
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines